Joachim Rautter
Co-Founder and Managing Director @ Peppermint Venture Partners
Berlin, Germany
Joachim Rautter is a Series A investor at Peppermint Venture Partners in Berlin focused on Medical and Health Care. Joachim Rautter is Founder at Drug Response Dx.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Joachim Rautter invests in
Stages Joachim Rautter invests in
Countries Joachim Rautter invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (20%)
- Health Care 1 (20%)
- Therapeutics 1 (20%)
- Biotechnology 1 (20%)
- Clinical Trials 1 (20%)
Stage
- Series A 1 (20%)
- Series B 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CryoTherapeutics
|
CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries. | $10.8M / Series B / Apr 02, 2024 | |
|
CryoTherapeutics
|
CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries. | $7.7M / Series B / Jun 27, 2019 | |
|
CryoTherapeutics
|
CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries. | $5.7M / Series B / Jul 07, 2016 | |
|
CryoTherapeutics
|
CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries. | $3.8M / Series A / May 06, 2014 | |
|
CryoTherapeutics
|
CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries. | Series A |
Co-Investors
PVP is a private venture capital firm based in Berlin, investing in early-stage healthcare companies across Europe with a focus on medical device, digital health, and platform technology companies. Peppermint VenturePartners was established in 2008 by Ingeborg Neumann, Dr. Joachim Rautter and Dr. Klaus Stöckemann.
Peppermint Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Joachim Rautter
Co-Founder and Managing Director
|
|||
Klaus Stoeckemann
Managing Director & Co-Founder
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Joachim Rautter invest in?
Joachim Rautter invests primarily in Medical, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Joachim Rautter?
Public channels for Joachim Rautter include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Joachim Rautter last invest?
The most recent investment recorded for Joachim Rautter closed in Apr 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
